Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.

Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J.

Clin Cancer Res. 2012 Jun 1;18(11):3090-9. doi: 10.1158/1078-0432.CCR-12-0445. Epub 2012 Apr 10.

2.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

3.

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

Grabowski B, Khosravan R, Wu JT, Vernillet L, Lademacher C.

Br J Clin Pharmacol. 2010 Jul;70(1):57-64. doi: 10.1111/j.1365-2125.2010.03667.x.

4.

Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.

Wong H, Theil FP, Cui Y, Marsters JC Jr, Khojasteh SC, Vernillet L, La H, Song X, Wang H, Morinello EJ, Deng Y, Hop CE.

Drug Metab Dispos. 2010 Jul;38(7):1029-38. doi: 10.1124/dmd.110.032680. Epub 2010 Apr 20.

PMID:
20406853
5.

Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.

Grabowski BA, Khosravan R, Vernillet L, Mulford DJ.

J Clin Pharmacol. 2011 Feb;51(2):189-201. doi: 10.1177/0091270010365549. Epub 2010 Mar 30.

PMID:
20354234
6.

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P.

Cancer Invest. 2009 Aug;27(7):756-63. doi: 10.1080/07357900802709159.

PMID:
19440934
7.

The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L.

J Clin Pharmacol. 2008 Sep;48(9):1014-24. doi: 10.1177/0091270008322035. Epub 2008 Jul 17.

PMID:
18635756
8.

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L.

Br J Clin Pharmacol. 2008 Mar;65(3):355-63. Epub 2007 Oct 22.

9.
10.

Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.

Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L.

J Clin Pharmacol. 2006 Aug;46(8):855-66.

PMID:
16855070
11.

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L.

J Clin Pharmacol. 2006 Jan;46(1):88-102.

PMID:
16397288
12.
13.

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.

Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ.

Am J Ther. 2005 Jan-Feb;12(1):22-34.

PMID:
15662289
14.

A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.

Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN.

Clin Cancer Res. 2003 Jul;9(7):2426-34.

15.

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, Faivre S, Sicard E, Germa C, Rodier JM, Vernillet L, Armand JP.

Ann Oncol. 2003 Apr;14(4):603-14.

PMID:
12649109
16.

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.

Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP.

J Clin Oncol. 2002 Nov 1;20(21):4303-12.

PMID:
12409328
17.

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Vasey PA, Roché H, Bisset D, Terret C, Vernillet L, Riva A, Ramazeilles C, Azli N, Kaye SB, Twelves CJ.

Br J Cancer. 2002 Nov 4;87(10):1072-8.

18.

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.

Campone M, Fumoleau P, Delecroix V, Deporte-Fety R, Perrocheau G, Vernillet L, Borg-Olivier O, Louboutin JP, Bissery MC, Riva A, Azli N.

Ann Oncol. 2001 Jul;12(7):909-18.

PMID:
11521794
19.

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Gelmon KA, Latreille J, Tolcher A, Génier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E.

J Clin Oncol. 2000 Dec 15;18(24):4098-108.

PMID:
11118471
20.

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.

Lortholary A, Maillard P, Delva R, Boisdron-Celle M, Perard D, Vernillet L, Besenval M, Gamelin E.

Eur J Cancer. 2000 Sep;36(14):1773-80.

PMID:
10974625
21.

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.

Ford HE, Cunningham D, Ross PJ, Rao S, Aherne GW, Benepal TS, Price T, Massey A, Vernillet L, Gruia G.

Br J Cancer. 2000 Jul;83(2):146-52.

22.

In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Combes O, Barré J, Duché JC, Vernillet L, Archimbaud Y, Marietta MP, Tillement JP, Urien S.

Invest New Drugs. 2000 Feb;18(1):1-5.

PMID:
10830136
23.

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G.

Clin Cancer Res. 2000 May;6(5):2012-20.

24.

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A.

J Clin Oncol. 2000 Jan;18(1):195-203.

PMID:
10623710
25.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1999 Jun;17(6):1897-905.

PMID:
10561231
26.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

de Jonge MJ, Verweij J, Planting AS, van der Burg ME, Stoter G, de Boer-Dennert MM, de Bruijn P, Brouwer E, Vernillet L, Sparreboom A.

Clin Cancer Res. 1999 Aug;5(8):2012-7.

27.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

Mathijssen RH, van Alphen RJ, de Jonge MJ, Verweij J, de Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G, Sparreboom A.

Anticancer Drugs. 1999 Jan;10(1):9-16.

PMID:
10194542
28.

Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography.

Chollet DF, Goumaz L, Renard A, Montay G, Vernillet L, Arnera V, Mazzo DJ.

J Chromatogr B Biomed Sci Appl. 1998 Oct 23;718(1):163-75.

PMID:
9832373
29.

A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique.

Rouini MR, Lotfolahi A, Stewart DJ, Molepo JM, Shirazi FH, Vergniol JC, Tomiak E, Delorme F, Vernillet L, Giguere M, Goel R.

J Pharm Biomed Anal. 1998 Sep;17(8):1243-7.

PMID:
9800643
30.

Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.

Haaz MC, Rivory L, Riché C, Vernillet L, Robert J.

Cancer Res. 1998 Feb 1;58(3):468-72.

31.

Noninterchangeability of specific radioimmunoassay and monoclonal antibody fluorescent polarization immunoassay in cyclosporine measurements.

Pape D, Vernillet L, Bellissant E, Bentue-Ferrer D, Allain H.

Fundam Clin Pharmacol. 1996;10(5):484-9.

PMID:
8902552
32.

Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients.

Vernillet L, Kovarik JM, Freiburghaus R, Schaub P, Mueller EA, Niederberger W, Zehender H.

Transplant Proc. 1994 Oct;26(5):2964-8. No abstract available.

PMID:
7940936
33.

Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation.

Kovarik JM, Vernillet L, Mueller EA, Freiburghaus R, Niederberger W, Kutz K.

Ther Drug Monit. 1994 Oct;16(5):519-25.

PMID:
7846753
34.

Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A.

Gardier AM, Mathé D, Guédeney X, Barré J, Benvenutti C, Navarro N, Vernillet L, Loisance D, Cachera JP, Jacotot B, et al.

Ther Drug Monit. 1993 Aug;15(4):274-80.

PMID:
8236361
35.

Trials of the bronchodilator activity of the xanthine analogue SDZ MKS 492 in healthy volunteers during a methacholine challenge test.

Foster RW, Jubber AS, Hassan NA, Franke B, Vernillet L, Denouel J, Carpenter JR, Small RC.

Eur J Clin Pharmacol. 1993;45(3):227-34.

PMID:
8276046
36.

Lack of effect of isradipine on cyclosporin pharmacokinetics.

Vernillet L, Bourbigot B, Codet JP, Le Saux L, Moal MC, Morin JF.

Fundam Clin Pharmacol. 1992;6(8-9):367-74.

PMID:
1292968
37.

Ocular distribution of cyclosporin A (Sandimmun) following systemic and topical administration to rabbits.

Vernillet L, Lundh RL, Acezat-Mispelter F, Goizel C, Humbert H, Pouliquen Y.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:150-8.

PMID:
1820870
38.

Assessment of immunosuppression by serum inhibition of alloreaction and measurement of cyclosporin A (CyA) serum levels in kidney graft recipients under CyA.

Chabannes D, Vernillet L, Cantarovich D, Humbert H, Vie H, Soulillou JP.

Transpl Int. 1990 Dec;3(4):189-94.

PMID:
2076168
39.

Influence of different parameters for the monitoring of cyclosporine.

Humbert H, Vernillet L, Cabiac MD, Barradas J, Billaud E.

Transplant Proc. 1990 Jun;22(3):1210-5. No abstract available.

PMID:
2349682
40.

French multicentre study: comparison of two specific and four nonspecific methods for Sandimmune (cyclosporine) blood and plasma (separated at 37 degrees C or at 22 degrees C) monitoring.

Vernillet L, Humbert H, Aupetit B, Berard M, Bertault-Peres P, Billaud E, Bizollon CA, Breteau M, Brisson AM, Codet JP, et al.

Transplant Proc. 1990 Jun;22(3):1218-23. No abstract available.

PMID:
2190383
41.

Lack of effect of spiramycin on cyclosporin pharmacokinetics.

Vernillet L, Bertault-Peres P, Berland Y, Barradas J, Durand A, Olmer M.

Br J Clin Pharmacol. 1989 Jun;27(6):789-94.

42.
43.

[Pharmacokinetics of cyclosporin A in patients with nephrotic syndrome].

Moulin B, Vernillet L, Dadoun C, Le Bigot JF, Godin M, Fillastre JP.

Nephrologie. 1989;10(1):17-22. French.

PMID:
2716940
44.

Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit.

Holt DW, Johnston A, Marsden JT, Vernillet L, Keown PA, Rosano TG, Shaw LM, Rosenthaler J.

Clin Chem. 1988 Jun;34(6):1091-6.

45.

Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome.

Vernillet L, Moulin B, Dadoun C, Le Bigot JF, Fillastre JP.

Transplant Proc. 1988 Apr;20(2 Suppl 2):529-35. No abstract available.

PMID:
3363653
46.

Small intestinal transplantation and cyclosporine predose calculation.

Lokiec F, Vernillet L, Le Bigot JF, Ricour C, Goulet O.

Transplant Proc. 1988 Apr;20(2 Suppl 2):491-3. No abstract available.

PMID:
3363651
47.

Attempt at photonic and ultrastructural immunohistochemical localization of cyclosporine A in rat kidney and liver.

Tricottet V, Reynès M, Vernillet L, Santelli G, Le Bigot JF, Fries D.

Transplant Proc. 1987 Feb;19(1 Pt 2):1221-2. No abstract available.

PMID:
3079017

Supplemental Content

Loading ...
Support Center